These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 37368521)

  • 1. The Essential Need for Trust When Transmission Risk Cannot Be Eliminated in HIV-Remission Trials.
    Rennie S; Henderson G; Phanuphak N; Kuczynski K; Colby D; Ormsby N; Kroon E; Hsu D; Likhitwonnawut U; Vasan S; Sacdalan C; Jupimai T; Butterworth O; Peay H
    Ethics Hum Res; 2023; 45(4):2-15. PubMed ID: 37368521
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HIV remission trial investigators' attitudes towards risk and risk mitigation in trials that include treatment interruption.
    Okumu EA; Henderson GE; Golin C; Kuczynski K; Ormsby NQ; Peay HL
    J Virus Erad; 2023 Jun; 9(2):100331. PubMed ID: 37416088
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Attitudes About Analytic Treatment Interruption (ATI) in HIV Remission Trials with Different Antiretroviral Therapy (ART) Resumption Criteria.
    Peay HL; Rennie S; Cadigan RJ; Gwaltney A; Jupimai T; Phanuphak N; Kroon E; Colby DJ; Ormsby N; Isaacson SC; Vasan S; Sacdalan C; Prueksakaew P; Benjapornpong K; Ananworanich J; Henderson GE
    AIDS Behav; 2022 May; 26(5):1504-1516. PubMed ID: 34997386
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ethical and practical considerations for mitigating risks to sexual partners during analytical treatment interruptions in HIV cure-related research.
    Dubé K; Kanazawa J; Dee L; Taylor J; Campbell DM; Brown B; Johnson MO; Saberi P; Sauceda JA; Sugarman J; Peluso MJ
    HIV Res Clin Pract; 2021 Feb; 22(1):14-30. PubMed ID: 33757411
    [No Abstract]   [Full Text] [Related]  

  • 5. Central Nervous System Safety During Brief Analytic Treatment Interruption of Antiretroviral Therapy Within 4 Human Immunodeficiency Virus Remission Trials: An Observational Study in Acutely Treated People Living With Human Immunodeficiency Virus.
    Hellmuth J; Muccini C; Colby DJ; Kroon E; de Souza M; Crowell TA; Chan P; Sacdalan C; Intasan J; Benjapornpong K; Tipsuk S; Puttamaswin S; Chomchey N; Valcour V; Sarnecki M; Tomaka F; Krebs SJ; Slike BM; Jagodzinski LL; Dumrongpisutikul N; Sailasuta N; Samboju V; Michael NL; Robb ML; Vasan S; Ananworanich J; Phanuphak P; Phanuphak N; Paul R; Spudich S
    Clin Infect Dis; 2021 Oct; 73(7):e1885-e1892. PubMed ID: 32916708
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analytical Treatment Interruption in HIV Trials: Statistical and Study Design Considerations.
    Zheng L; Tierney C; Bosch RJ
    Curr HIV/AIDS Rep; 2021 Oct; 18(5):475-482. PubMed ID: 34213731
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recommendations for analytical antiretroviral treatment interruptions in HIV research trials-report of a consensus meeting.
    Julg B; Dee L; Ananworanich J; Barouch DH; Bar K; Caskey M; Colby DJ; Dawson L; Dong KL; Dubé K; Eron J; Frater J; Gandhi RT; Geleziunas R; Goulder P; Hanna GJ; Jefferys R; Johnston R; Kuritzkes D; Li JZ; Likhitwonnawut U; van Lunzen J; Martinez-Picado J; Miller V; Montaner LJ; Nixon DF; Palm D; Pantaleo G; Peay H; Persaud D; Salzwedel J; Salzwedel K; Schacker T; Sheikh V; Søgaard OS; Spudich S; Stephenson K; Sugarman J; Taylor J; Tebas P; Tiemessen CT; Tressler R; Weiss CD; Zheng L; Robb ML; Michael NL; Mellors JW; Deeks SG; Walker BD
    Lancet HIV; 2019 Apr; 6(4):e259-e268. PubMed ID: 30885693
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is it ethical to isolate study participants to prevent HIV transmission during trials with an analytical treatment interruption?
    Eyal N; Magalhaes M
    J Infect Dis; 2019 Jul; 220(220 Suppl 1):S19-S21. PubMed ID: 31264688
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of Short-Term Antiretroviral Therapy Interruption on Levels of Integrated HIV DNA.
    Strongin Z; Sharaf R; VanBelzen DJ; Jacobson JM; Connick E; Volberding P; Skiest DJ; Gandhi RT; Kuritzkes DR; O'Doherty U; Li JZ
    J Virol; 2018 Jun; 92(12):. PubMed ID: 29593048
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phospholipid Metabolism Is Associated with Time to HIV Rebound upon Treatment Interruption.
    Giron LB; Papasavvas E; Yin X; Goldman AR; Tang HY; Palmer CS; Landay AL; Li JZ; Koethe JR; Mounzer K; Kostman JR; Liu Q; Montaner LJ; Abdel-Mohsen M
    mBio; 2021 Feb; 12(1):. PubMed ID: 33622719
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Perspectives on Analytical Treatment Interruptions in People Living with HIV and Their Health Care Providers in the Landscape of HIV Cure-Focused Studies.
    Lau JSY; Smith MZ; Allan B; Martinez C; Power J; Lewin SR; McMahon JH
    AIDS Res Hum Retroviruses; 2020 Apr; 36(4):260-267. PubMed ID: 31608648
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Origin of Rebound Plasma HIV Includes Cells with Identical Proviruses That Are Transcriptionally Active before Stopping of Antiretroviral Therapy.
    Kearney MF; Wiegand A; Shao W; Coffin JM; Mellors JW; Lederman M; Gandhi RT; Keele BF; Li JZ
    J Virol; 2016 Feb; 90(3):1369-76. PubMed ID: 26581989
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Considerations for Increasing Racial, Ethnic, Gender, and Sexual Diversity in HIV Cure-Related Research with Analytical Treatment Interruptions: A Qualitative Inquiry.
    Dubé K; Kanazawa J; Campbell C; Boone CA; Maragh-Bass AC; Campbell DM; Agosto-Rosario M; Stockman JK; Diallo DD; Poteat T; Johnson M; Saberi P; Sauceda JA
    AIDS Res Hum Retroviruses; 2022 Jan; 38(1):50-63. PubMed ID: 33947268
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk to Nonparticipants in HIV Remission Studies With Treatment Interruption: A Symposium.
    Eyal N; Deeks SG
    J Infect Dis; 2019 Jul; 220(220 Suppl 1):S1-S4. PubMed ID: 31264687
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Balancing Statistical Power and Risk in HIV Cure Clinical Trial Design.
    Lau JSY; Cromer D; Pinkevych M; Lewin SR; Rasmussen TA; McMahon JH; Davenport MP
    J Infect Dis; 2022 Aug; 226(2):236-245. PubMed ID: 35104873
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lessons learned from HIV antiretroviral treatment interruption trials.
    Wen Y; Bar KJ; Li JZ
    Curr Opin HIV AIDS; 2018 Sep; 13(5):416-421. PubMed ID: 29878912
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human Immunodeficiency Virus Transmission Risk in Analytical Treatment Interruption Studies: Relational Factors and Moral Responsibility.
    Dawson L
    J Infect Dis; 2019 Jul; 220(220 Suppl 1):S12-S15. PubMed ID: 31264689
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ethics of treatment interruption trials in HIV cure research: addressing the conundrum of risk/benefit assessment.
    Henderson GE; Peay HL; Kroon E; Cadigan RJ; Meagher K; Jupimai T; Gilbertson A; Fisher J; Ormsby NQ; Chomchey N; Phanuphak N; Ananworanich J; Rennie S
    J Med Ethics; 2018 Apr; 44(4):270-276. PubMed ID: 29127137
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A collaborative, multidisciplinary approach to HIV transmission risk mitigation during analytic treatment interruption.
    Peluso MJ; Dee L; Campbell D; Taylor J; Hoh R; Rutishauser RL; Sauceda J; Deeks SG; Dubé K
    J Virus Erad; 2020 Feb; 6(1):34-37. PubMed ID: 32175090
    [TBL] [Abstract][Full Text] [Related]  

  • 20. "I Know That I Was a Part of Making a Difference": Participant Motivations for Joining a Cure-Directed HIV Trial with an Analytical Treatment Interruption.
    Neergaard R; Jones NL; Roebuck C; Rendle KA; Barbati Z; Peterson B; Tebas P; Mounzer K; Metzger D; Montaner LJ; Dube K; Barg FK
    AIDS Res Hum Retroviruses; 2023 Aug; 39(8):414-421. PubMed ID: 35979886
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.